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Abstract – 150 words  
Within the realm of medical care, Self-Identified Race and Ethnicity (SIRE) categories are 
promoted as an inexpensive tool to identify underlying genotypic diversity. Scientific opinion is 
divided about the adequacy of SIRE to serve this function. If genetic diversity can guide medical 
decisions, it is important to know the effectiveness of genetic screening via SIRE. Proper 
development of self-reported measures such as SIRE requires sensitivity and specificity studies.  
These types of formal evaluation are largely absent for SIRE. To begin this formal process, we 
estimate the sensitivity of SIRE in screening for variant Single Nucleotide Polymorphism (SNP). 
Our results indicate that the current use of SIRE is inadequate to screen for selected 
biotransformation related SNP in the N-Acetyl Transferase pathway.  The widespread usage of 
SIRE to screen for genotypic diversity could promote erroneous assignment of patients to disease 
risk or therapeutic categories.   
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 Introduction 
Self-Identified Race and Ethnicity (SIRE) has been the topic of a number of conferences, 
editorial and opinion papers that suggest it is not an adequate pre-screen test for medically 
significant genotypic diversity (Love 2001, Collins FS 2004, Wolf SF 2005, Duster 2007).  
Despite this lack of consensus opinion, SIRE continues to be promoted for use as a tool to 
predict the presence of disease risk genes (Freeman et al 2006) or response to pharmacologic 
treatments (Wolf 2005).  The scientific rationale for the use of SIRE as a genetic screening tool 
often rests on observed population-level differences in the proportion of variant alleles. In the 
development of tools for medical application, population-level proportions are not sufficient to 
justify this application. Development of a predictive marker to prevent disease occurrence or 
enhance treatment response requires the estimation of the risks associated with both accurate and 
inaccurate categorical assignment. In this paper, we have selected a SNP with the potential for 
clinical application. The following text provides prevalence rates of a SNP from four SIRE 
defined populations that were created to identify cancer related genes.  To push this concept 
further, we then estimate the probability that SIRE alone predicts the presence of a variant SNP. 
Our results suggest that in a sample derived from populations across the globe, SIRE cannot 
satisfactorily identify the presence of variant SNP. 
First do no harm is the guiding principle when contemplating the introduction of a new 
medical procedure.  This directive commands us to develop a clear sense of the potential for 
harm that would accompany the use of SIRE as a genetic screener. Rather than a sole focus on 
the potential for positive effects, the translation of genetic-marker guided therapy into clinical 
practice also needs a clear assessment of the additional risks imposed with using SIRE to guide 
medical decisions.  Such risks include the potential for harm associated with an incorrect 
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assignment of genetic constitution based on SIRE, the probability that a SIRE response will 
incorrectly assign disease risk, and the likelihood that a patient will be incorrectly assigned to a 
therapeutic regimen based on a SIRE response.  To fully assess the utility of SIRE as a genetic 
marker, we need to compare the probability of benefit with the probability for causing harm. 
SIRE is a self-reported measure and one obvious source of harm is the risk of 
misclassification. Although there have been formal discussions of the potential connection 
between human bio-geographic variation and categorization of race within medicine (Tishoff and 
Kidd 2004), a working definition for SIRE has never been subjected to formal evaluation.  
Scientific research involving the use of SIRE utilizes a categorization scheme that is largely 
defined by governmental agencies such as the U.S. Bureau of the Census 
(www.censusbureau.org). These categorizations may be of use in social science, but their 
validity in encompassing biological factors relevant for clinical evaluation is often unclear. To 
cite one example, The National Cancer Institute SNP500Cancer Database 
(http://www.nci.nih.gov) divides contributed samples into four SIRE categories – Caucasian, 
African / African American, Native American / Hispanic, and Pacific Rim. The website provides 
further detail on the country of origin for the samples but nothing concerning the logic used to 
assign individuals.  
There are research methods that can be used to assess accuracy, validity, and consistency 
of SIRE as a surrogate for genetic constitution. These methods have been used to evaluate 
similar data. Family history, like SIRE, is a self-reported measure used as a surrogate for shared 
genetic constitution (http://www.cdc.gov). Family members share their genes, as well as their 
environment, lifestyles and habits.  The clinical validity of self-reported family history for cancer 
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has been evaluated using an evidence-based review of precision and accuracy (Murff, Spigel, 
and Syngal 2004). 
Precision reflects the reproducibility of the report. There are multiple factors that 
decrease the precision of a family history report, including poor patient-physician 
communication, increasing distance of relation to the affected relative, and lack of disease in the 
reporting patient. Accuracy captures the how well a test actually measures the value it intends to 
measure. A similar set of factors diminish the accuracy of self-reported cancer family history. 
The best accuracy is obtained for patients with active colon or breast cancer who identify first-
degree relatives who have had colon or breast cancer (Murff, Spigel, and Syngal 2004). All other 
site-specific family cancer history reports lack precision and accuracy. The results of self-
reported family cancer history studies indicate that the precision and accuracy of SIRE reports 
should be thoroughly evaluated prior to any implementation as a genetic screening tool. 
Translating genetic knowledge from population-level statistics to individual-level risk 
assessment is another potential contributor to SIRE-induced clinical harm. The argument used to 
justify the use of SIRE as a genetic screening tool is based on population differences in the 
distribution of variant alleles. In medical epidemiologic research, it has been long understood 
that population distribution cannot be used as the indicator of individual risk. Within the setting 
of medical care, the important goal is to identify the probability that an individual patient has the 
genes of interest. One seeks to know, e.g., the likelihood that an individual man has a gene that 
substantially increases his risk of prostate cancer, or the chance that an individual patient has the 
pharmacogenetics constitution to derive benefit from a specific medication. The application of a 
screening tool is the appropriate mechanism to determine these odds but the underlying 
mechanics of this application have not been explored .   
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Screening is a logical first-step process to distinguish between categories of genetically 
determined response. SIRE is being promoted as an appropriate screening tool within the realm 
of medical care.  Clinically useful screening tests need to be robust enough to identify high risk 
individuals embedded in a non-selected sample. SIRE is conceptually designed to create a few 
broadly defined categories. This concept is in direct opposition to sampling strategies employed 
in most gene identity studies, which have always capitalized on the power of a highly select 
sample of related individuals.  Lack of precision in the definition of categories, then, is a 
significant source of variation in estimating the sensitivity of SIRE as a screening tool to identify 
underlying SNP. 
Screening has a recognized place in the ascertainment of medical history, assignment of 
clinical risk, and determination of treatment appropriateness. The practice of evidence-based 
medicine now requires a process of formal evaluation for all screening tools.  When SIRE is 
associated with SNP, then the distinction is being made between persons having a wild-type SNP 
and those who have a variant SNP. In this report, we present an approach to evaluate the 
sensitivity of SIRE as a screener for the presence of selected variant SNP. To conduct this 
technical evaluation of SIRE, we use the nomenclature present on the publicly available National 
Cancer Institute SNP500Cancer Database. (http://www.nci.nih.gov.) The SNP500 Cancer 
database was not created to support definitive evaluation of SIRE as a screening tool, but it is 
ideal for this conceptual evaluation for a number of reasons. It is one of the publicly available 
datasets where SIRE and SNP data are available for this type of analyses. The database contains 
samples from persons across the globe. This sample composition more closely mimics the 
clinical environment for the application of SIRE guided medical treatment. The stability of 
genotyping technology has been assured for all samples. This technical report is designed to 
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present a strategy that can be used to design future formal testing of SIRE as a SNP screening 
tool.   
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Results 
 Although screening is a conceptually simple idea, the algebra underlying translation from 
biomarker to clinical tool is not. In this report, we compare the information content of three 
statistical approaches widely used in genetics, medicine and social science to detect the presence 
of population-level differences - Prevalence; Screening measures, and Linear Regression. 
Prevalence is a simple population-based calculation of percentage. Screening tests measurement 
evaluates performance and quantifies the probability of misclassification errors.  Linear 
regression (LR) is also a prediction statistic that further measures the association between a 
marker and a related trait.  The widespread usage of LR by the scientific community makes it an 
intuitively useful way of illustrating the association between SIRE and SNPs. Each measure is 
mathematically consistent, but what do they tell us about the use of SIRE to guided SNP allele 
detection? 
[Table 1 about here.] 
 Prevalence is a straight forward method for identifying population differences in the 
proportion of individuals with a specific SNP as shown in Table 1. Each row contains percent 
distribution of a single allele in the three NAT genes for a SIRE-defined group. Each NAT gene 
has three allelic forms determined by the combination of  wt for wild type and var for variant.  
For the NAT1 rs1057126, the AA allele is least common. The percent of persons in each SIRE 
category with this allele ranges from 8.2% (Caucasians) to 25.0% (African/African American). 
There is no known risk associated with any of these genes. They were selected solely for 
calculations in this report.   
 What kinds of questions are we asking when comparisons are made? With the 
percentages in the bottom row, we can ask – ‘Does any one group have a greater than expected 
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percent of persons with the variant SNP?’ This implies a comparison between percents observed 
in the combined sample (bottom row) and a single SIRE category.  Statistical comparison of 
Caucasians and African/African American categories yield a result indicates statistical 
differences. A similar pattern of allelic difference can be observed when comparing the Pacific 
Rim category (4.4%) with Caucasians (19.8%) for RS1801280. Again, there is a statistically 
significant between group differences in prevalence of the NAT1 rs1801280 CC allele. This type 
of statistical difference appears to suggest the utility of SIRE as a screening tool for at least two 
NAT1 alleles. 
 
----Table 2 about here---- 
 Does a statistically significant difference in population prevalence translate into a 
clinically useful screening question?  To be clinically useful, a screening test must maximize 
identification of persons have an elevated risk (‘true positive’) and minimize misclassification of 
who do not have an elevated risk (‘false positive’). In addition, medical treatment or lack thereof 
is not without its own inherent risks. Therefore, it is also important to have a screening test that 
accurately identifies persons without risk (‘true negative’). Finally, it is important that the test 
results do not erroneously deny treatment to a person who might benefit (‘false negative’). In 
Table 2, we present sensitivity estimates (i.e. Is the SNP present?) and specificity (i.e. Is the SNP 
absent?).   
 The performance of self-reported racial identity as a screening tool for the rs1057126 AA 
allele and the rs1801280 CC allele appears to be much less reliable than prevalence statistics 
would suggest. When a person self identifies as African / African American, there is only a 37% 
probability that the AA allele is present. Similarly, there is only a 34% probability that the CC 
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allele is present when a person self-identifies as a Caucasian. Each of these is a low probability 
events are well below the 85 percent standard used to judge clinical utility for screening tests 
(www.cochrane.org; (http://www.healthit.ahrq.gov). Clearly in the case of these two alleles, a 
positive response to an individual SIRE category is not a clinically useful screening tool for the 
presence of this SNP.  
Alternatively, what if the critical decision rested on the probability that a trait was 
absent? Specificity statistics are higher for both responses (76%, respectively). If the medical 
decision involved application of a treatment with potential toxicity, then increasing the certainty 
associated with a negative test result would be important and prevent unnecessary exposure to a 
toxic treatment. For each gene, not being a member of the African / African-American category 
(AA allele) or the Caucasian category (CC allele) would only be accurate 76% of the time.   
---Table 3 here--- 
Does SIRE predict the presence of a single variant SNP?  A non-clinical approach to this 
question could also involve the use of a regression model. Regression models are a statistical tool 
that is most familiar to social scientists evaluating multivariable effects. Table 3 shows results 
from a modeling process. There are SIRE group separate models shown in each row, i.e. each 
separate response is evaluated for its likelihood to predict the presence of the variant allele. The 
models were computed using either the sensitivity estimate (results shown) or the prevalence 
(models not shown). None of the SIRE variables achieved statistical significance when 
prevalence was used.  Is there added information for study design that can be gained from this 
statistical approach?  In each of the models the t-statistic results suggests a large amount of 
unexplained variance in the association between SIRE and the presence of the AA (Table 3A 
results) or CC (Table 3B results). Biopsychosocial models of health and disease incorporate 
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concepts that combine allelic data with other factors to compare and contrast biological and 
sociological influences on disease risk. More work is needed to develop appropriate statistical 
tools. These statistical models suggest the size of the gap between SNP and the ability of SIRE to 
predict the presence of variant SNP. 
Discussion 
This is a technical report describing the application of sensitivity estimation to SIRE when it is 
used as a screening tool for the presence of variant SNP.  SIRE has been promoted as a screening 
tool for the assignment of future disease risk or the selection of medications in clinical practice. 
An assumption underlying this practice is that SIRE accurately indicates the presence of 
clinically important SNP. By formulating SIRE as a screening tool, we have been able to begin 
the process of articulating a formal test of SIRE. It is our hope that with this approach, the 
discussion of race and medicine can be taken out of the realm of opinion.  Treatment decision-
making has significant consequences for patients. Physicians are more comfortable using tools 
that are evidence-based. Social scientific research has provided evidence that SIRE is a complex 
measure capturing genetic and environmental factors (Hayward et al 2000).   
Is there a place for SIRE-guided medical treatment? This analysis would suggest that 
SIRE cannot be used as it is currently defined to screen for variant SNP in the N-Acetyl 
Transferase system. These findings need to be replicated in other treatment decisions and for 
other SNP. Our analysis indicates that SIRE performs well below the recommended 85 percent 
minimum sensitivity standard when applied as a screening test to indicate an underlying variant 
SNP. In a white paper (2003), The British National Health Service evaluated the future 
application of genetic testing in clinical medicine but did not recommend use of SIRE as a 
screening tool for clinically important SNP.  SIRE lacks adequate sensitivity as a screening tool 
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and its application in clinical practice has the potential for erroneously assuming the presence of 
a variant SNP when it is not present.   
Statistical Sample and Methods 
SIRE definition and Sampling Frame 
SNP500CANCER Dataset 
The Cancer Genome Anatomy Project: SNP500Cancer Database was created to re-sequence 102 
anonymous reference samples as well as the Human Diversity Panel, consisting of 280 persons 
from a variety of populations world-wide from the Coriell Biorepository (Camden, NJ) (Cann et 
al 2002, Packer et al 2006). The Project seeks to validate known or newly discovered genetic 
variants of potential importance to studies of cancer and other diseases.  Initial inclusion of a 
SNP in the database is based upon review of the literature with input from intramural and 
extramural investigators. There is currently heavy weighting towards non-synonymous SNP (i.e., 
those that result in an amino acid substitution).  For purposes of this sensitivity analysis, the least 
common form is designated as a variant. For the NAT1 rs1057126 SNP, the AA genotype was 
designated as the variant and is present among 18.0 % of the combined sample (Case Plus 
Human Diversity Panel). A similar decision process was applied to each of the other SNP 
categories. For rs 15561 the AA genotype was designated as variant (22.2%). For the rs 
18011280 SNP, the TT genotype was designated as variant (9.4 %). The SIRE sensitivity 
calculation, then estimates the probability that a patient report of specific category within SIRE 
indicates the presence of a low frequency variant SNP.  
Sensitivity is a ratio comparing the performance of a screening test with a different so-
called gold standard indicator (Loong 2003). To develop the analysis shown in this report, we 
started with the standard 2x2 Table.  
[Insert Table 4 about here] 
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The sensitivity of SIRE is compared with the gold standard – Molecular confirmation of a 
SNP in Table 4.  A represents all persons who report group membership and have the SNP of 
interest. A divided by A + C indicates the sensitivity of a self-report. There are other measures of 
test performance that can be obtained from this approach. False positive (A / A+B) directly 
calculates the probability that a self-report is incorrect. Likelihood ratio (LR) is another 
evidence-based ratio that is used to compare test sensitivity and false positive rates.  The 
interpretation of LR balances the tension between a test that is highly sensitive but also generates 
large rates of false positives. In the assignment of treatment, each individual circumstance 
requires determining whether greater harm comes from missing a person with the trait of interest 
or misclassifying a person who does not have the trait.  
The SNP500Cancer Database is a broad sampling of SNP standardized for future cancer 
risk research.  It was not designed for screening test development.  The rationale for using this 
database for sensitivity analysis is based on the idea that it contains consensus-derived genetic 
markers derived from geographically dispersed populations that have been assigned to broad 
categories of SIRE. One future technical issue to resolve is the development of a more 
appropriate dataset. 
Table 1 shows the percent or prevalence of variant SNP for each SIRE group across the 
three SNP categories used in this analysis. The analysis shown in Table 2 could have been 
accomplished using a variety of statistical methods. We chose this approach because it is the 
preferred application for medical decision purposes (Loong 2003).  Clinical decision-making 
requires that we are able to address the likelihood that our test leads to the false assumption that a 
person has a SNP when, in fact, it is not present.  Sensitivity and Specificity are companion 
statistics. In this technical report, we are solely focused on examining the technical issues 
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surrounding the ability of SIRE to indicate the presence of a variant SNP. In a future studies 
advocating clinical application for SIRE as a screening tool, both its sensitivity and specificity 
should be presented. 
Sources of variation in Sensitivity 
The calculation of sensitivity is generally a population-based statistic which capitalizes on the 
concepts underlying the classical Chi-X2 statistic which is a ratio comparing the observed 
frequency of an event with the expected frequency based on random occurrence. The proportion 
of individuals in the specific sample with the gold standard marker influences the estimated 
sensitivity of a screening test.  For example, if a particular variant SNP is present in 100 percent 
of members of one SIRE category, then SIRE would accurately reflect the underlying presence 
of the SNP. Screening tests are known to have falsely elevated sensitivity rates when the 
prevalence of a characteristic is low in the population.  The estimated test sensitivity can be 
corrected for chance agreement using a method developed by Coughlin and Pickle (1992).   
Creating an experimental sample for the assessment of test performance is another approach to 
distinguishing a main effect of SIRE and interaction between SIRE and SNP variants (Goldman 
and Flanders 2007).   
 
Conclusion 
SIRE appears to be a poor screening tool for variant N-acetyl transferase SNPs, well below the 
recommended level of 85% specificity. Physicians generally ought not recommend screening 
tests where the risk of a false positive is high and potential harms could come from an erroneous 
screening result. Nor should SIRE be utilized as a screening test for clinically relevant variant 
SNPs without good evidence of significant sensitivity, since significant harms can come from 
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treating a patient based on an erroneous assumption of a variant SNP. Further research should be 
done to more carefully test this specificity for other relevant SNPs, but our analysis suggests that 
the current evidence gives little reason, in most cases, to correlate SIRE with any given SNP.
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 Table 1: Prevalence Variant N-Acetyl Transferase (NAT) SNP allele within Self-Identified Racial and Ethnic (SIRE) 
Category: Percent allele type, total number within SIRE category. 
 
   SIRE Category   
 
NAT SNP 
African / African 
American 
N (%) 
Caucasian 
 
N (%) 
Hispanic / Native 
American 
N (%) 
Pacific Rim 
 
N (%) 
Combined Sample 
 
N (%) 
Genotype / Allelic Distribution       
rs1057126      
- wt / wt 25 (25.0) 63 (64.9) 19 (26.8) 42  (37.2) 149 (39.1) 
- wt / var 52 (52.0) 26 (26.8) 37 (52.1) 47 (41.6) 162 (42.5) 
- var / var 23 (23.0)  8 (08.2) 15 (21.1) 24 (21.2)  70 (18.4) 
- Total column 100 97 71 113 381 
- % SIRE  26.1 25.4 18.6 29.7%  
rs15561      
- wt / wt 21 (21.4) 52 (55.9) 18 (25.3) 29 (25.9) 120 (32.1) 
- wt / var 49 (50.0) 29 (31.2) 37 (52.1) 54 (48.2) 169 (45.2) 
- var / var 28 (28.6) 12 (12.9) 16 (22.5) 29 (25.9) 85 (22.7) 
- Total column  98 93 71 112 374 
- % SIRE 26.2 24.9 19.0 29.9  
rs1801280      
- wt / wt 44 (50.0) 30 (31.2) 31 (43.1) 78 (70.3) 183 (49.9) 
- wt / var 38 (43.2) 47 (49.0) 34 (47.2) 29 (26.1) 148 (40.3) 
- var / var   6 (06.8) 19 (19.8)   7 (09.7)   4 (03.6)   36 (09.8) 
- Total column  88 96 72 111 367 
- % SIRE 24.0 26.2 19.6 30.2  
Note: Identification based on categories in the SNP500Cancer Database. Denominator = Cancer Control Sample plus Population Diversity Panel. See 
http://www.nci.nih.gov. wt / wt = Wild type allele; wt / var = Heterozygous allele; var/var = Homozygous allele. Prevalence = [Number with designated allele 
divided by Number with other alleles]. These are calculated within each SIRE category. Denominator is also shown for each SIRE category. Percents within 
columns do not add to 100 due to rounding. 
 
N
a
t
u
r
e
 
P
r
e
c
e
d
i
n
g
s
 
:
 
h
d
l
:
1
0
1
0
1
/
n
p
r
e
.
2
0
0
8
.
1
5
2
4
.
1
 
:
 
P
o
s
t
e
d
 
1
7
 
J
a
n
 
2
0
0
8
 
 
Table 2: Screening test performance: SIRE performance as a indictor of variant NAT allele (var). 
 
 
 Variant Present *   Variant Absent *  
 
Not 
Caucasian 
(NC)# 
Caucasian 
(C) @ 
Sensitivity 
(%) 
Caucasian 
(C) @ 
Not 
Caucasian 
(NC)# 
Specificity 
(%) 
Genotype       
rs1057126  
 - %  SIRE  69.7 35.0  64.9 30.3 
 
 
- Test Parameter   85.3   42.3 
rs15561 
 - %  SIRE  74.2 44.1  55.9 26.8  
 
- Test Parameter   70.5   17.0 
rs1801280 
 - %  SIRE  64.1 68.8  31.2 35.9  
 
- Test Parameter 
  
47.2 
  
16.3 
Note: Identification based on categories in the SNP500Cancer Database. See http://www.nci.nhi.gov. @Taken from Table 1. # calculated by 
combining groups. Presence of variant determined by laboratory testing.   
x Sensitivity of SIRE response = [VAR+NC / (VAR+NC plus VAR+C)];   
x Specificity of SIRE response = [VAR- C / (VAR- C plus VAR- NC)]. 
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Table 3: Does SIRE predict the presence of a single variant SNP? Trial with 2 NAT1 SNPs. 
 
A. Dependent Variable: NAT1 Sensitivity 1057126 
Model   
Standardized 
Coefficients 
B t Sig. 95% Confidence Interval for B 
1 (Constant)   8.668 .013 20.146 59.854 
 Caucasians  / Others 
-.854 -2.319 .146 -61.109 
 
18.309 
 
2 (Constant)  3.999 .057 -2.679 73.212 
 African / Others 
-.098 -.140 .902 -78.358 
 
73.425 
 
3 (Constant)  3.847 .061 -3.946 70.613 
 Hispanic / Others 
.210 .304 .790 -69.293 
 
79.826  
 
4 (Constant)  4.894 .039 2.853 44.347 
  Pacific Rim / Others .088 .124 .912 -40.293 42.693 
 
 
B. Dependent Variable: NAT1 Sensitivity 1801280 
Model   
Standardized 
Coefficients 
B t Sig. 95% Confidence Interval for B 
1 (Constant)  5.271 .034 3.227 31.907 
 
Caucasians  / Others 
.966 5.286 .034 6.553 
 
63.913 
 
2 (Constant)   2.179 
 
.161 
 
-27.066 
 
82.599 
 
African / Others 
-.153 -.218 .847 -115.232 
 
104.099 
 
3 (Constant)  2.302 .148 -24.949 82.349 
 
Hispanic / Others 
-.255 -.373 .745 -116.597 
 
97.997 
 
4 (Constant)  2.942 .099 -14.560 77.493 
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Pacific Rim / Others 
-.558 -.952 .442 -112.420 71.686 
 
Note:  Each row represents a separate model with SIRE recoded as a dummy variable. To create the variable, the group of interest is coded as 1 
and all others are coded as 0.  Using a mixed group sample, the model reflects the probability that a specific SIRE reflects the presence of a single 
SNP.  Models use SNP sensitivity estimate from Table 2.  
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Table 4: Sample 2x2 table for comparison of SNP data with SIRE 
                           Molecular Confirmation of SNP 
SIRE Membership Yes No 
Yes A B 
No C D 
 A + C B + D 
 
 
 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
08
.1
52
4.
1 
: P
os
te
d 
17
 J
an
 2
00
8
